124 related articles for article (PubMed ID: 18839307)
21. The impact of
Wang Y; Wu Z; Zhou L; Lu J; Wang Y; Lin Y; Xu S; Ye Y; Peng J; Zhang J; Yin W; Lu J
Gland Surg; 2020 Aug; 9(4):925-935. PubMed ID: 32953602
[TBL] [Abstract][Full Text] [Related]
22. SGCE Promotes Breast Cancer Stem Cells by Stabilizing EGFR.
Zhao L; Qiu T; Jiang D; Xu H; Zou L; Yang Q; Chen C; Jiao B
Adv Sci (Weinh); 2020 Jul; 7(14):1903700. PubMed ID: 32714745
[TBL] [Abstract][Full Text] [Related]
23. EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both
Xia L; Zheng ZZ; Liu JY; Chen YJ; Ding JC; Xia NS; Luo WX; Liu W
Clin Transl Immunology; 2020 May; 9(5):e01135. PubMed ID: 32373345
[TBL] [Abstract][Full Text] [Related]
24. Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers.
Ogden A; Bhattarai S; Sahoo B; Mongan NP; Alsaleem M; Green AR; Aleskandarany M; Ellis IO; Pattni S; Li XB; Moreno CS; Krishnamurti U; Janssen EA; Jonsdottir K; Rakha E; Rida P; Aneja R
Sci Rep; 2020 Feb; 10(1):3009. PubMed ID: 32080212
[TBL] [Abstract][Full Text] [Related]
25. Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer.
Canonici A; Browne AL; Ibrahim MFK; Fanning KP; Roche S; Conlon NT; O'Neill F; Meiller J; Cremona M; Morgan C; Hennessy BT; Eustace AJ; Solca F; O'Donovan N; Crown J
Ther Adv Med Oncol; 2020; 12():1758835919897546. PubMed ID: 32064003
[TBL] [Abstract][Full Text] [Related]
26. Expression of tumor-associated antigens in breast cancer subtypes.
Curigliano G; Bagnardi V; Ghioni M; Louahed J; Brichard V; Lehmann FF; Marra A; Trapani D; Criscitiello C; Viale G
Breast; 2020 Feb; 49():202-209. PubMed ID: 31869767
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor (
Zakaria Z; Zulkifle MF; Wan Hasan WAN; Azhari AK; Abdul Raub SH; Eswaran J; Soundararajan M; Syed Husain SNA
Onco Targets Ther; 2019; 12():7749-7756. PubMed ID: 31571924
[TBL] [Abstract][Full Text] [Related]
28. Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer.
Fenn K; Maurer M; Lee SM; Crew KD; Trivedi MS; Accordino MK; Hershman DL; Kalinsky K
Clin Breast Cancer; 2020 Feb; 20(1):80-86. PubMed ID: 31570268
[TBL] [Abstract][Full Text] [Related]
29. Ampelopsin E Reduces the Invasiveness of the Triple Negative Breast Cancer Cell Line, MDA-MB-231.
Tieng FYF; Latifah SY; Md Hashim NF; Khaza'ai H; Ahmat N; Gopalsamy B; Wibowo A
Molecules; 2019 Jul; 24(14):. PubMed ID: 31323836
[TBL] [Abstract][Full Text] [Related]
30. Novel Prognostic Markers in Triple-Negative Breast Cancer Discovered by MALDI-Mass Spectrometry Imaging.
Phillips L; Gill AJ; Baxter RC
Front Oncol; 2019; 9():379. PubMed ID: 31139569
[TBL] [Abstract][Full Text] [Related]
31. Dimensional Analysis of CD44
Tan B; Kanoko M; Tan G; Bachtiar A; Munir D
Open Access Maced J Med Sci; 2019 Feb; 7(4):526-528. PubMed ID: 30894906
[TBL] [Abstract][Full Text] [Related]
32. Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs.
Zhang Y; Li J; Lai XN; Jiao XQ; Xiong JP; Xiong LX
Cells; 2019 Feb; 8(2):. PubMed ID: 30754684
[TBL] [Abstract][Full Text] [Related]
33. Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis.
Ilie SM; Bacinschi XE; Botnariuc I; Anghel RM
Breast Cancer (Dove Med Press); 2018; 10():177-194. PubMed ID: 30538542
[TBL] [Abstract][Full Text] [Related]
34. Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines.
Simiczyjew A; Dratkiewicz E; Van Troys M; Ampe C; Styczeń I; Nowak D
Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30227653
[TBL] [Abstract][Full Text] [Related]
35. CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer.
Wang Z; Sau S; Alsaab HO; Iyer AK
Nanomedicine; 2018 Jun; 14(4):1441-1454. PubMed ID: 29678787
[TBL] [Abstract][Full Text] [Related]
36. Tissue Inhibitor of Metalloprotease-2 (TIMP-2): Bioprocess Development, Physicochemical, Biochemical, and Biological Characterization of Highly Expressed Recombinant Protein.
Chowdhury A; Brinson R; Wei B; Stetler-Stevenson WG
Biochemistry; 2017 Dec; 56(49):6423-6433. PubMed ID: 29140689
[TBL] [Abstract][Full Text] [Related]
37. Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.
Quintero M; Adamoski D; Reis LMD; Ascenção CFR; Oliveira KRS; Gonçalves KA; Dias MM; Carazzolle MF; Dias SMG
BMC Cancer; 2017 Nov; 17(1):727. PubMed ID: 29115931
[TBL] [Abstract][Full Text] [Related]
38. Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer.
Darvishi B; Farahmand L; Majidzadeh-A K
Mol Ther Nucleic Acids; 2017 Jun; 7():164-180. PubMed ID: 28624192
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers.
Levva S; Kotoula V; Kostopoulos I; Manousou K; Papadimitriou C; Papadopoulou K; Lakis S; Koukoulias K; Karavasilis V; Pentheroudakis G; Balassi E; Zagouri F; Kaklamanos IG; Pectasides D; Razis E; Aravantinos G; Papakostas P; Bafaloukos D; Rallis G; Gogas H; Fountzilas G
Cancer Genomics Proteomics; 2017; 14(3):181-195. PubMed ID: 28446533
[TBL] [Abstract][Full Text] [Related]
40. Oncogenic MCT-1 activation promotes YY1-EGFR-MnSOD signaling and tumor progression.
Tseng HY; Chen YA; Jen J; Shen PC; Chen LM; Lin TD; Wang YC; Hsu HL
Oncogenesis; 2017 Apr; 6(4):e313. PubMed ID: 28394354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
